The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPVG.L Regulatory News (PVG)

  • There is currently no data for PVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

PREMIER PET CARE PLAN LAUNCHED IN FRANCE

9 Jun 2016 07:00

RNS Number : 6753A
Premier Veterinary Group PLC
09 June 2016
 

 

 

PREMIER VETERINARY GROUP plc

("PVG" or "the Company")

 

PREMIER PET CARE PLAN LAUNCHED IN FRANCE AS PREMIER VETOPLAN

 

London, UK, 9 June 2016 - Premier Veterinary Group plc (LSE: PVG) announces that its preventative healthcare program for pets, branded "Premier Pet Care Plan" ("PPCP") in the UK, has been launched in France as Premier VetoPlan ("PVP") following the recent France Vet exhibition.

 

The first Business Development Manager and support training manager have been appointed and the initial primary focus will be on Paris and the Ile de France region that surrounds the capital. At the France Vet exhibition, the first contract for PVP was signed with a clinic in Toulouse in the south of the country.

 

The available market for preventative healthcare programs for pets across France is estimated at over 7 million dogs - similar to the UK - and over 11 million cats - more than 30% higher than the UK (Source: FACCO, France). There are approximately 6,000 veterinary practices in France.

 

Dominic Tonner, Chief Executive Officer of PVG, commented:

 

"Following our successful rollout of PPCP in the Netherlands, we have been reviewing the market opportunity in several other major European territories. We have now launched a bespoke preventative healthcare program for France where we see an exciting opportunity for rapid growth."

 

For further information, please contact:

 

Premier Veterinary Group plc Tel: +44 (0)117 970 4130

Dominic Tonner, Chief Executive Officer

Daniel Smith, Chief Financial Officer

 

Square1 Consulting Tel: +44 (0)207 929 5599

David Bick/Brian Alexander

 

 

Note to Editors:

 

PVG's services to third party veterinary practices, through its wholly-owned subsidiary Premier Vet Alliance Limited ("PVA"), include the administration and support of a preventative healthcare program for pets branded "Premier Pet Care Plan"; and the operation of a buying group (the "PVA Buying Group") in the UK and Ireland, which offers enhanced discounts to member practices on pharmaceutical and consumable spending. In the US, Premier Pet Care Plan is marketed through the Company's wholly-owned subsidiary, Premier Vet Alliance (US) Limited.

 

Premier Pet Care Plan is a structured, preventative healthcare program for cats, dogs and rabbits and is available only through veterinary practices. The program is seen as a way of providing gold standard care for pets at an affordable price for the client, by way of fixed monthly payments.

   

Premier Pet Care Plan uses a clinical approach to prevention, as this is the most effective method of ensuring illnesses are diagnosed more quickly and not given a chance to advance. What truly sets Premier Pet Care Plan apart is its unique approach of offering an end-to-end solution and support to the practice, which has been proven to work extremely well. PVA works alongside practices to create a tailor-made, cost-effective service for clients, one that delivers excellent care to their patients and significantly improves practice performance.

 

The PVA Buying Group, is now the UK's largest veterinary buying group without group interests in veterinary practices or veterinary wholesalers offering its members the best discounts across the industry on pharmaceutical and consumable spend.

 

For further details: http://www.premiervetalliance.co.uk/

 

 

This announcement includes "forward-looking statements" which include all statements other than statements of historical facts, including, without limitation, those regarding the Company's financial position, business strategy, plans and objectives of management for future operations, and any statements preceded by, followed by or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will", "can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements involve known and unknown risks, uncertainties and other important factors beyond the Company's control that could cause the actual results, performance or achievements of the Company to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this announcement. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. As a result of these factors, readers are cautioned not to rely on any forward-looking statement.

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUGUBCQUPQGMR
Date   Source Headline
21st Jul 201010:54 amRNSForm 8.5 (EPT/NON-RI)
20th Jul 201011:35 amRNSForm 8.5 (EPT/NON-RI)
20th Jul 201011:00 amRNSForm 8.5 (EPT/RI)
20th Jul 201010:46 amRNSForm 8.3 - [Ark Therapeutics]
19th Jul 201011:39 amRNSForm 8.5 (EPT/RI)
19th Jul 201011:33 amRNSForm 8.5 (EPT/RI)- Amendment 15/07
19th Jul 201011:26 amRNSForm 8.3 - Ark Therapeutics
16th Jul 201012:07 pmRNSForm 8.5 (EPT/RI)
15th Jul 20101:06 pmRNSForm 8.3 - Ark Therapeutics Group PLC
13th Jul 20107:00 amRNSARK UPDATE AND BOARD CHANGES
9th Jul 201010:16 amRNSForm 8.3 - Ark Therapeutics Group PLC - Amendment
8th Jul 201010:27 amRNSForm 8.3 - Ark Therapeutics Group PLC
7th Jul 20101:54 pmPRNForm 8.3 - Ark Therapeutic Group Plc
7th Jul 201011:50 amRNSForm 8.5 (EPT/NON-RI)
6th Jul 20102:49 pmPRNForm 8.3 - Ark Therapeutics Groups Plc
6th Jul 201011:36 amRNSForm 8.5 (EPT/NON-RI)
2nd Jul 20102:15 pmPRNForm 8.3 - Ark Therapeutic Group Plc
2nd Jul 201011:45 amRNSForm 8.5 (EPT/NON-RI)
1st Jul 201011:36 amRNSForm 8.5 (EPT/RI)
30th Jun 20102:45 pmPRNForm 8.3 - Ark Therapeutic Group
30th Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
29th Jun 20103:06 pmPRNForm 8.3 - Ark Therapeutic Group Plc
25th Jun 20102:34 pmPRNForm 8.3 - Ark Therapeutics Group Plc
25th Jun 201010:52 amRNSForm 8.5 (EPT/RI)-Amendment
24th Jun 201011:39 amRNSForm 8.5 (EPT/NON-RI)
24th Jun 201010:23 amRNSForm 8.5 (EPT/RI)
23rd Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
23rd Jun 201011:39 amRNSForm 8.5 (EPT/RI)
22nd Jun 20102:50 pmPRNForm 8.3 - Ark Therapeutics
22nd Jun 201011:41 amRNSForm 8.5 (EPT/RI)
21st Jun 20102:48 pmRNSForm 8.3 - Ark Therapeutics Group plc
21st Jun 20102:07 pmPRNForm 8.3 - ARK THERAPEUTIC PLC
21st Jun 20101:16 pmRNSForm 8.3 - Ark Therapeutics Plc
21st Jun 201010:48 amRNSForm 8.5 (EPT/RI)
18th Jun 20102:33 pmPRNForm 8.3 - Ark Therapeutics Group Plc
18th Jun 201012:19 pmRNSForm 8.3 - Ark Therapeutics Plc
18th Jun 201011:45 amRNSForm 8.5 (EPT/NON-RI)
18th Jun 201011:02 amRNSHolding(s) in Company
17th Jun 20102:42 pmPRNForm 8.3 - Ark Therapeutics Group
17th Jun 20102:41 pmRNSForm 8.3 - Ark Therapeutics Group PLC
17th Jun 20101:47 pmRNSForm 8.3 - Ark Therapeutics Plc
17th Jun 201011:32 amRNSForm 8.5 (EPT/NON-RI)
16th Jun 201011:25 amRNSForm 8.5 (EPT/RI)
16th Jun 20109:19 amRNSForm 8.5 (EPT/NON-RI)
15th Jun 20103:12 pmRNSForm 8.3 - Ark Therapeutics Group PLC
15th Jun 20102:43 pmPRNForm 8.3 - Ark Therapeutics Group Plc
15th Jun 201012:38 pmRNSForm 8.3 - Ark Therapeutics Plc
15th Jun 20109:47 amRNSForm 8.5 (EPT/NON-RI)
14th Jun 20103:08 pmRNSForm 8.3 - Ark Therapeutics Group PLC
14th Jun 20101:30 pmRNSForm 8.3 - Ark Therapeutics Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.